Influenza A Virus, H5N1 Subtype Clinical Trial
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and
adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to
generate an immune response to homologous and to antigenically distant heterologous H5
influenza virus strains.
The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.
|Source||Biomedical Advanced Research and Development Authority|
|Status||Active, not recruiting|
|Start date||March 15, 2018|
|Completion date||September 2, 2019|